On Target Laboratories

On Target Laboratories is a privately-held diagnostics company pioneering intraoperative molecular imaging agents to improve surgical oncology outcomes. Founded in 2011 and based in West Lafayette, Indiana, the company has advanced its lead agent, CYTALUX®, which targets folate receptor-alpha (FRα) positive cancers. Their platform utilizes small-molecule technology for rapid targeting and flexible dosing, with the goal of reducing residual disease and improving patient survival. The company's pipeline targets major cancer types including ovarian, lung, prostate, and colorectal cancers, addressing a significant unmet need in surgical precision.

Small-molecule targeted fluorescent imaging agents for real-time intraoperative visualization of cancer. The platform leverages rapid pharmacokinetics and specific biomarker targeting (e.g., folate receptor-alpha) to illuminate malignant tissue.

On Target competes in the intraoperative imaging market with other fluorescent agent developers (e.g., indocyanine green (ICG)-based approaches, other targeted fluorophores) and alternative technologies like radio-guided surgery and advanced preoperative imaging. Its differentiation is its specific small-molecule targeting of cancer biomarkers, aiming for higher specificity than non-targeted agents.